{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T08:41:59Z","timestamp":1780648919117,"version":"3.54.1"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T00:00:00Z","timestamp":1662076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T00:00:00Z","timestamp":1662076800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Johann Wolfgang Goethe-Universit\u00e4t, Frankfurt am Main"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Pediatr"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Iron deficiency is the primary cause of anaemia worldwide and is particularly common among children and adolescents. Intravenous (IV) iron therapy is recommended for paediatric patients with certain comorbidities or if oral iron treatment has been unsuccessful. IV ferric carboxymaltose (FCM) has recently been approved by the US Food and Drug Administration for use in children aged\u2009&gt;\u20091\u00a0year. This narrative review provides an overview of the available publications on the efficacy and safety of IV FCM in children and adolescents. A literature search using PubMed and Embase yielded 153 publications; 33 contained clinical data or reports on clinical experience relating to IV FCM in subjects\u2009&lt;\u200918\u00a0years of age and were included in the review. No prospective, randomised controlled studies on the topic were found. Most publications were retrospective studies or case reports and included patients with various underlying conditions or patients with inflammatory bowel disease. Efficacy data were included in 27\/33 publications and improvements in anaemia, and\/or iron status parameters were reported in 26 of them. Safety data were included in 25\/33 publications and were in line with the adverse events described in the prescribing information.<\/jats:p><jats:p><jats:italic>Conclusion:<\/jats:italic> The available publications indicate that IV FCM, a nanomedicine with a unique and distinctive therapeutic profile, is an effective and generally well-tolerated treatment for iron deficiency or iron deficiency anaemia in children and adolescents. Despite the wealth of retrospective evidence, prospective, randomised controlled trials in the paediatric setting are still necessary.<jats:table-wrap><jats:table><jats:tbody>\n                    <jats:tr>\n                      <jats:td colspan=\"2\"><jats:bold>What is Known:<\/jats:bold><jats:italic>\u2022\u00a0<\/jats:italic><jats:italic>Iron deficiency and iron deficiency anaemia are usually managed using oral iron therapy, but intravenous iron therapy is recommended for certain paediatric patients.<\/jats:italic><jats:italic>\u2022 Intravenous ferric carboxymaltose (FCM) has recently been approved in the US for use in children aged &gt; 1 year.<\/jats:italic><\/jats:td>\n                    <\/jats:tr>\n                    <jats:tr>\n                      <jats:td colspan=\"2\"><jats:bold>What is New:<\/jats:bold><jats:italic>\u2022 Despite evidence that FCM is effective and generally well tolerated in children and adolescents, so far, only retrospective studies, non-randomised uncontrolled prospective studies, or case reports have been published in full.<\/jats:italic><jats:italic>\u2022 There is a strong need for prospective, randomised controlled trials on FCM in the paediatric setting.<\/jats:italic><\/jats:td>\n                    <\/jats:tr>\n                  <\/jats:tbody><\/jats:table><\/jats:table-wrap><\/jats:p>","DOI":"10.1007\/s00431-022-04582-w","type":"journal-article","created":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T19:02:31Z","timestamp":1662145351000},"page":"3781-3793","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Intravenous ferric carboxymaltose for the management of iron deficiency and iron deficiency anaemia in children and adolescents: a review"],"prefix":"10.1007","volume":"181","author":[{"given":"Ayseg\u00fcl","family":"Aksan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred","family":"Zepp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangeetha","family":"Anand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,2]]},"reference":[{"key":"4582_CR1","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1186\/s13045-021-01202-2","volume":"14","author":"S Safiri","year":"2021","unstructured":"Safiri S, Kolahi AA, Noori M, Nejadghaderi SA, Karamzad N, Bragazzi NL, Sullman MJM, Abdollahi M, Collins GS, Kaufman JS, Grieger JA (2021) Burden of anemia and its underlying causes in 204 countries and territories, 1990\u20132019: results from the Global Burden of Disease Study 2019. J Hematol Oncol 14:185. https:\/\/doi.org\/10.1186\/s13045-021-01202-2","journal-title":"J Hematol Oncol"},{"key":"4582_CR2","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/S0140-6736(15)60865-0","volume":"387","author":"A Lopez","year":"2016","unstructured":"Lopez A, Cacoub P, Macdougall IC, Peyrin-Biroulet L (2016) Iron deficiency anaemia. Lancet 387:907\u2013916. https:\/\/doi.org\/10.1016\/S0140-6736(15)60865-0","journal-title":"Lancet"},{"key":"4582_CR3","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1111\/joim.13004","volume":"287","author":"MD Cappellini","year":"2020","unstructured":"Cappellini MD, Musallam KM, Taher AT (2020) Iron deficiency anaemia revisited. J Intern Med 287:153\u2013170. https:\/\/doi.org\/10.1111\/joim.13004","journal-title":"J Intern Med"},{"key":"4582_CR4","doi-asserted-by":"publisher","DOI":"10.4084\/mjhid.2020.041","volume":"12","author":"E Mantadakis","year":"2020","unstructured":"Mantadakis E, Chatzimichael E, Zikidou P (2020) Iron deficiency anemia in children residing in high and low-income countries: risk factors, prevention, diagnosis and therapy. Mediterr J Hematol Infect Dis 12:e2020041. https:\/\/doi.org\/10.4084\/mjhid.2020.041","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"4582_CR5","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1016\/S0140-6736(20)30752-2","volume":"396","author":"GBD","year":"2019","unstructured":"GBD\u00a02019\u00a0Risk Factors Collaborators (2020) Global burden of 87 risk factors in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 396:1223\u20131249. https:\/\/doi.org\/10.1016\/S0140-6736(20)30752-2","journal-title":"Lancet"},{"issue":"Suppl 6","key":"4582_CR6","doi-asserted-by":"publisher","first-page":"1663S","DOI":"10.3945\/ajcn.117.156018","volume":"106","author":"LF van der Merwe","year":"2017","unstructured":"van der Merwe LF, Eussen SR (2017) Iron status of young children in Europe. Am J Clin Nutr 106(Suppl 6):1663S-1671S. https:\/\/doi.org\/10.3945\/ajcn.117.156018","journal-title":"Am J Clin Nutr"},{"key":"4582_CR7","doi-asserted-by":"publisher","first-page":"330","DOI":"10.3390\/nu8060330","volume":"8","author":"PM Gupta","year":"2016","unstructured":"Gupta PM, Perrine CG, Mei Z, Scanlon KS (2016) Iron, anemia, and iron deficiency anemia among young children in the United States. Nutrients 8:330. https:\/\/doi.org\/10.3390\/nu8060330","journal-title":"Nutrients"},{"key":"4582_CR8","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1159\/000488865","volume":"72","author":"P Christian","year":"2018","unstructured":"Christian P, Smith ER (2018) Adolescent undernutrition: global burden, physiology, and nutritional risks. Ann Nutr Metab 72:316\u2013328. https:\/\/doi.org\/10.1159\/000488865","journal-title":"Ann Nutr Metab"},{"key":"4582_CR9","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s00431-020-03597-5","volume":"179","author":"Mattiello V, Schmugge M, Hengartner H, von der Weid N, Renella R; SPOG Pediatric Hematology Working Group","year":"2020","unstructured":"Mattiello V, Schmugge M, Hengartner H, von der Weid N, Renella R; SPOG Pediatric Hematology Working Group (2020) Diagnosis and management of iron deficiency in children with or without anemia: consensus recommendations of the SPOG Pediatric Hematology Working Group. Eur J Pediatr 179:527\u2013545. https:\/\/doi.org\/10.1007\/s00431-020-03597-5","journal-title":"Eur J Pediatr"},{"key":"4582_CR10","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jpeds.2019.12.040","volume":"219","author":"JM Powers","year":"2020","unstructured":"Powers JM, Nagel M, Raphael JL, Mahoney DH, Buchanan GR, Thompson DI (2020) Barriers to and facilitators of iron therapy in children with iron deficiency anemia. J Pediatr 219:202\u2013208. https:\/\/doi.org\/10.1016\/j.jpeds.2019.12.040","journal-title":"J Pediatr"},{"key":"4582_CR11","unstructured":"British Society of Paediatric Gastroenterology, Hepatology and Nutrition (2014)\u00a0Diagnosis and management of anaemia in children with IBD\u00a0Diagnosis and management of anaemia in children with IBD. Available at: http:\/\/mail.bspghan.org.uk\/documents\/Iron%20Deficiency%20PIBD%20Jan%202015-2. (Accessed Feb\u00a02022)"},{"key":"4582_CR12","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1097\/MPG.0000000000002885","volume":"71","author":"A Goyal","year":"2020","unstructured":"Goyal A, Zheng Y, Albenberg LG, Stoner NL, Hart L, Alkhouri R, Hampson K, Ali S, Cho-Dorado M, Goyal RK, Grossman A (2020) Anemia in children with inflammatory bowel disease: a position paper by the IBD Committee of the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 71:563\u2013582. https:\/\/doi.org\/10.1097\/MPG.0000000000002885","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"4582_CR13","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease (2012) Kidney Int Suppl 2:279\u2013335."},{"key":"4582_CR14","unstructured":"National Institute for Health and Care Excellence (NICE) (2021) Chronic kidney disease: assessment and management. Available at: https:\/\/www.nice.org.uk\/guidance\/ng203\/resources\/chronic-kidney-disease-assessment-and-management-pdf-66143713055173. (Accessed Feb\u00a02022)"},{"key":"4582_CR15","doi-asserted-by":"publisher","unstructured":"Allen RP, Picchietti DL, Auerbach M, Cho YW, Connor JR, Earley CJ, Garcia-Borreguero D, Kotagal S, Manconi M, Ondo W, Ulfberg J, Winkelman JW;\u00a0International Restless Legs Syndrome Study Group (IRLSSG) (2018) Evidence-based and consensus clinical practice guidelines for the iron treatment of restless legs syndrome\/Willis-Ekbom disease in adults and children: an IRLSSG task force report. Sleep Med 41:27\u201344. https:\/\/doi.org\/10.1016\/j.sleep.2017.11.1126","DOI":"10.1016\/j.sleep.2017.11.1126"},{"key":"4582_CR16","doi-asserted-by":"publisher","unstructured":"Domell\u00f6f M, Szitanyi P, Simchowitz V, Franz A, Mimouni F (2018)\u00a0ESPGHAN\/ESPEN\/ESPR\/CSPEN working group on pediatric parenteral nutrition\u00a0ESPGHAN\/ESPEN\/ESPR\/CSPEN guidelines on pediatric parenteral nutrition: iron and trace minerals. Clin Nutr 37(6 Pt B):2354\u20132359. https:\/\/doi.org\/10.1016\/j.clnu.2018.06.949","DOI":"10.1016\/j.clnu.2018.06.949"},{"key":"4582_CR17","unstructured":"Ferinject (ferric carboxymaltose) summary of product characteristics (2021) Available at: https:\/\/www.medicines.org.uk\/emc\/product\/5910\/smpc. (Accessed Feb\u00a02022)"},{"key":"4582_CR18","unstructured":"Injectafer prescribing information (2022) Available at: https:\/\/injectafer.com\/. (Accessed May 2022)"},{"key":"4582_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.590527","volume":"7","author":"RS Gaspar","year":"2020","unstructured":"Gaspar RS, Silva-Lima B, Magro F, Alcobia A, da Costa FL, Feio J (2020) Non-biological complex drugs (NBCDs): complex pharmaceuticals in need of individual robust clinical assessment before any therapeutic equivalence decision. Front Med (Lausanne) 7:590527. https:\/\/doi.org\/10.3389\/fmed.2020.590527","journal-title":"Front Med (Lausanne)"},{"key":"4582_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.nano.2020.102178","volume":"26","author":"N Nikravesh","year":"2020","unstructured":"Nikravesh N, Borchard G, Hofmann H, Philipp E, Fl\u00fchmann B, Wick P (2020) Factors influencing safety and efficacy of intravenous iron-carbohydrate nanomedicines: from production to clinical practice. Nanomedicine 26:102178. https:\/\/doi.org\/10.1016\/j.nano.2020.102178","journal-title":"Nanomedicine"},{"issue":"Suppl 1","key":"4582_CR21","doi-asserted-by":"publisher","first-page":"A172","DOI":"10.1136\/ejhpharm-2018-eahpconf.371","volume":"25","author":"I Athiana","year":"2018","unstructured":"Athiana I, Waldenvik K, Paulsson M, Engstrand-Lilja H, Lundberg A, Finkel Y, Nystr\u00f6m N (2018) 5PSQ-017 safety of intravenous ferric carboxymaltose in treatment of iron deficiency in children under 2 years with intestinal failure. Eur J Hosp Pharm 25(Suppl 1):A172. https:\/\/doi.org\/10.1136\/ejhpharm-2018-eahpconf.371","journal-title":"Eur J Hosp Pharm"},{"issue":"Suppl 1","key":"4582_CR22","doi-asserted-by":"publisher","first-page":"S337","DOI":"10.1093\/ecco-jcc\/jjy222.575","volume":"13","author":"L Cococcioni","year":"2019","unstructured":"Cococcioni L, Elzein A, Sider S, Chadokufa S, Buckingham R, Ocholi A, Shah N, McCartney S, Saliakellis E, Borrelli O, Kiparissi F (2019) P451 safety and efficacy of ferric carboxymaltose (FCM) for the treatment of iron deficiency anaemia in paediatric patients affected by inflammatory bowel disease (pIBD). J Crohns Colitis 13(Suppl 1):S337. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjy222.575","journal-title":"J Crohns Colitis"},{"issue":"Suppl 1","key":"4582_CR23","first-page":"248","volume":"112","author":"G Crighton","year":"2017","unstructured":"Crighton G, Gurung A, Barnes C (2017) P-590 ferric carboxymaltose in children less than 14 years of age. Vox Sang 112(Suppl 1):248\u2013249","journal-title":"Vox Sang"},{"issue":"Suppl 1","key":"4582_CR24","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1182\/blood-2020-136137","volume":"136","author":"C Dargan","year":"2020","unstructured":"Dargan C, Simon D, Fleishman N, Goyal A, Sharma M (2020) A study examining the efficacy of ferric carboxymaltose in a large pediatric cohort. Blood 136(Suppl 1):17\u201318. https:\/\/doi.org\/10.1182\/blood-2020-136137","journal-title":"Blood"},{"issue":"Suppl 1","key":"4582_CR25","doi-asserted-by":"publisher","first-page":"A380","DOI":"10.1093\/sleep\/zsaa056.997","volume":"43","author":"LM DelRosso","year":"2020","unstructured":"DelRosso LM, Ferri R, Allen RP, Chen ML, Kotagal S, Picchietti D (2020) 1001 intravenous ferric carboxymaltose for restless legs syndrome in children and adolescents. Sleep 43(Suppl 1):A380. https:\/\/doi.org\/10.1093\/sleep\/zsaa056.997","journal-title":"Sleep"},{"key":"4582_CR26","doi-asserted-by":"publisher","unstructured":"DelRosso LM, Picchietti DL, Ferri R (2021) Comparison between oral ferrous sulfate and intravenous ferric carboxymaltose in children with restless sleep disorder. Sleep 44:zsaa155. https:\/\/doi.org\/10.1093\/sleep\/zsaa155","DOI":"10.1093\/sleep\/zsaa155"},{"issue":"Suppl 1","key":"4582_CR27","doi-asserted-by":"publisher","first-page":"S267","DOI":"10.1093\/ecco-jcc\/jju027.496","volume":"9","author":"S Hachemi","year":"2015","unstructured":"Hachemi S, Mutalib M, Chadokufa S, Huggett B, Sider S, Shah N, Whitley L, McCartney S, Kiparissi F (2015) P377 assessment of safety and efficacy of ferric carboxymaltose (Ferinject\u00ae) in the management of iron deficiency with anaemia (IDA) or without anaemia in children and adolescents with inflammatory bowel disease (IBD). J Crohns Colitis 9(Suppl 1):S267. https:\/\/doi.org\/10.1093\/ecco-jcc\/jju027.496","journal-title":"J Crohns Colitis"},{"key":"4582_CR28","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1111\/jpc.14686","volume":"55","author":"MHS Hong","year":"2019","unstructured":"Hong MHS, Singh H, Hinds R (2019) Letter to the editor. J Paediatr Child Health 55:1515\u20131516. https:\/\/doi.org\/10.1111\/jpc.14686","journal-title":"J Paediatr Child Health"},{"key":"4582_CR29","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.jpeds.2020.02.071","volume":"222","author":"AE Jacobson-Kelly","year":"2020","unstructured":"Jacobson-Kelly AE, Stanek JR, Powers JM, Dotson JL, O\u2019Brien SH (2020) Trends in anemia, iron, therapy, and transfusion in hospitalized pediatric patients with inflammatory bowel disease. J Pediatr 222:141-145.e1. https:\/\/doi.org\/10.1016\/j.jpeds.2020.02.071","journal-title":"J Pediatr"},{"key":"4582_CR30","doi-asserted-by":"publisher","first-page":"E215","DOI":"10.1002\/ajh.26165","volume":"96","author":"SE Kirk","year":"2021","unstructured":"Kirk SE, Scheurer ME, Bernhardt MB, Mahoney DH, Powers JM (2021) Phosphorus levels in children treated with intravenous ferric carboxymaltose. Am J Hematol 96:E215\u2013E218. https:\/\/doi.org\/10.1002\/ajh.26165","journal-title":"Am J Hematol"},{"issue":"4 Suppl","key":"4582_CR31","doi-asserted-by":"publisher","first-page":"E261","DOI":"10.1016\/j.dld.2017.09.052","volume":"49","author":"D Knafelz","year":"2017","unstructured":"Knafelz D, Acton N, Angelakopoulou A, Sider S, Chadokufa S, Shah N, Kiparissi F (2017) P048 Intravenous ferric carboxymaltose is effective and safe for the treatment of iron deficiency anaemia in children affected by inflammatory bowel disease. Dig Liver Dis 49(4 Suppl):E261. https:\/\/doi.org\/10.1016\/j.dld.2017.09.052","journal-title":"Dig Liver Dis"},{"key":"4582_CR32","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/1471-230X-14-184","volume":"14","author":"MW Laass","year":"2014","unstructured":"Laass MW, Straub S, Chainey S, Virgin G, Cushway T (2014) Effectiveness and safety of ferric carboxymaltose treatment in children and adolescents with inflammatory bowel disease and other gastrointestinal diseases. BMC Gastroenterol 14:184. https:\/\/doi.org\/10.1186\/1471-230X-14-184","journal-title":"BMC Gastroenterol"},{"key":"4582_CR33","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.28614","volume":"67","author":"H Ozsahin","year":"2020","unstructured":"Ozsahin H, Schaeppi M, Bernimoulin M, Allard M, Guidard C, van den Ouweland F (2020) Intravenous ferric carboxymaltose for iron deficiency anemia or iron deficiency without anemia after poor response to oral iron treatment: benefits and risks in a cohort of 144 children and adolescents. Pediatr Blood Cancer 67:e28614. https:\/\/doi.org\/10.1002\/pbc.28614","journal-title":"Pediatr Blood Cancer"},{"key":"4582_CR34","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1111\/bcp.13493","volume":"84","author":"M Papadopoulos","year":"2018","unstructured":"Papadopoulos M, Patel D, Korologou-Linden R, Goto E, Soondrum K, Fell JME, Epstein J (2018) Safety and efficacy of parenteral iron in children with inflammatory bowel disease. Br J Clin Pharmacol 84:694\u2013699. https:\/\/doi.org\/10.1111\/bcp.13493","journal-title":"Br J Clin Pharmacol"},{"key":"4582_CR35","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1111\/apa.15178","volume":"109","author":"A Posod","year":"2020","unstructured":"Posod A, Schaefer B, Mueller T, Zoller H, Kiechl-Kohlendorfer U (2020) Hypophosphatemia in children treated with ferric carboxymaltose. Acta Paediatr 109:1491\u20131492. https:\/\/doi.org\/10.1111\/apa.15178","journal-title":"Acta Paediatr"},{"key":"4582_CR36","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.jpeds.2016.09.053","volume":"180","author":"JM Powers","year":"2017","unstructured":"Powers JM, Shamoun M, McCavit TL, Adix L, Buchanan GR (2017) Intravenous ferric carboxymaltose in children with iron deficiency anemia who respond poorly to oral iron. J Pediatr 180:212\u2013216. https:\/\/doi.org\/10.1016\/j.jpeds.2016.09.053","journal-title":"J Pediatr"},{"key":"4582_CR37","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1097\/MPG.0000000000003003","volume":"72","author":"N Sasankan","year":"2021","unstructured":"Sasankan N, Duncan H, Curtis L, McGuckin C, Shannon C, Barclay A, Fraser S, Nair M, Russell RK, Hansen R (2021) Ferric carboxymaltose across all ages in paediatric gastroenterology shows efficacy without increased safety concerns. J Pediatr Gastroenterol Nutr 72:506\u2013510. https:\/\/doi.org\/10.1097\/MPG.0000000000003003","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"Suppl 1","key":"4582_CR38","first-page":"A13788","volume":"140","author":"JA Spinner","year":"2019","unstructured":"Spinner JA, Puri K, Powers J, Dasari T, Tunuguntla H, Choudhry S, Cabrera AG, Shah M, Dreyer WJ, Denfield SW, Price JF (2019) Abstract 13788: intravenous iron replacement therapy with ferric carboxymaltose is safe and effective in pediatric patients with heart failure. Circulation 140(Suppl 1):A13788","journal-title":"Circulation"},{"key":"4582_CR39","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1007\/s00431-017-2995-8","volume":"176","author":"MLN Tan","year":"2017","unstructured":"Tan MLN, Windscheif PM, Thornton G, Gaynor E, Rodrigues A, Howarth L (2017) Retrospective review of effectiveness and safety of intravenous ferric carboxymaltose given to children with iron deficiency anaemia in one UK tertiary centre. Eur J Pediatr 176:1419\u20131423. https:\/\/doi.org\/10.1007\/s00431-017-2995-8","journal-title":"Eur J Pediatr"},{"key":"4582_CR40","doi-asserted-by":"publisher","unstructured":"Carman N, Muir R, Lewindon P (2019) Ferric carboxymaltose in the treatment of iron deficiency in pediatric inflammatory bowel disease. Transl Pediatr 8:28\u201334. https:\/\/doi.org\/10.21037\/tp.2019.01.01","DOI":"10.21037\/tp.2019.01.01"},{"key":"4582_CR41","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1080\/00365521.2016.1224381","volume":"52","author":"S Val\u00e9rio de Azevedo","year":"2017","unstructured":"Val\u00e9rio de Azevedo S, Maltez C, Lopes AI (2017) Pediatric Crohn\u2019s disease, iron deficiency anemia and intravenous iron treatment: a follow-up study. Scand J Gastroenterol 52:29\u201333. https:\/\/doi.org\/10.1080\/00365521.2016.1224381","journal-title":"Scand J Gastroenterol"},{"key":"4582_CR42","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1159\/000507823","volume":"13","author":"EA Abdelmahmuod","year":"2020","unstructured":"Abdelmahmuod EA, Yassin MA (2020) Iron deficiency anemia-induced lymphocytopenia in a young female. Case Rep Oncol 13:793\u2013797. https:\/\/doi.org\/10.1159\/000507823","journal-title":"Case Rep Oncol"},{"key":"4582_CR43","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.transci.2018.05.026","volume":"57","author":"I Beverina","year":"2018","unstructured":"Beverina I, Macellaro P, Parola L, Brando B (2018) Extreme anemia (Hb 33 g\/L) in a 13-year-old girl: is the transfusion always mandatory? Transfus Apher Sci 57:512\u2013514. https:\/\/doi.org\/10.1016\/j.transci.2018.05.026","journal-title":"Transfus Apher Sci"},{"issue":"Suppl 2","key":"4582_CR44","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.28321","volume":"67","author":"C Daignault","year":"2020","unstructured":"Daignault C, Gulati N, Olive A, Ruan W, Fishman D, Narine K (2020) Poster #758 Gastric Burkitt lymphoma diagnosed after work up for severe iron deficiency anemia: a case report. Pediatr Blood Cancer 67(Suppl 2):e28321. https:\/\/doi.org\/10.1002\/pbc.28321","journal-title":"Pediatr Blood Cancer"},{"key":"4582_CR45","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1136\/archdischild-2018-316405","volume":"105","author":"RE Harris","year":"2020","unstructured":"Harris RE, Garrick V, Curtis L, Russell RK (2020) Skin staining due to intravenous iron extravasation in a teenager with Crohn\u2019s disease. Arch Dis Child 105:362. https:\/\/doi.org\/10.1136\/archdischild-2018-316405","journal-title":"Arch Dis Child"},{"key":"4582_CR46","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1093\/bja\/aer435","volume":"108","author":"CW H\u00f6nemann","year":"2012","unstructured":"H\u00f6nemann CW, Doll D, Kampmeier T, Ertmer C, Hagemann O, Hahnenkamp K (2012) Anaemia tolerance: bridging with intravenous ferric carboxymaltose in a patient with acute post-haemorrhagic anaemia. Br J Anaesth 108:167\u2013168. https:\/\/doi.org\/10.1093\/bja\/aer435","journal-title":"Br J Anaesth"},{"issue":"5 Suppl","key":"4582_CR47","doi-asserted-by":"publisher","first-page":"S70","DOI":"10.1016\/j.anai.2019.08.099","volume":"123","author":"M Joseph","year":"2019","unstructured":"Joseph M, Szafron V, Yang B, Srivaths L, Anvari S, Castells M, Noroski L (2019) M030 Ferric carboxymaltose desensitization in refractory idiopathic iron-deficiency anemia, iron-infusion anaphylaxis, severe atopy and hypertryptasemia. Ann Allergy Asthma Immunol 123(5 Suppl):S70. https:\/\/doi.org\/10.1016\/j.anai.2019.08.099","journal-title":"Ann Allergy Asthma Immunol"},{"key":"4582_CR48","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1053\/j.jvca.2011.07.012","volume":"26","author":"A P\u00e9rez-Ferrer","year":"2012","unstructured":"P\u00e9rez-Ferrer A, Gredilla E, de Vicente J, Laporta Y (2012) Cardiac surgery without blood products in a Jehovah\u2019s Witness child with factor VII deficiency. J Cardiothorac Vasc Anesth 26:651\u2013653. https:\/\/doi.org\/10.1053\/j.jvca.2011.07.012","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"4582_CR49","doi-asserted-by":"publisher","unstructured":"Shrinkhal, Singh A, Agrawal A, Yadav P, Verma R (2020) Sudden vision loss as first clinical manifestation of anaemic retinopathy. J Clin Diag Res 14:ND01\u2013ND03. https:\/\/doi.org\/10.7860\/JCDR\/2020\/44332.13706","DOI":"10.7860\/JCDR\/2020\/44332.13706"},{"key":"4582_CR50","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1136\/flgastro-2019-101242","volume":"11","author":"RE Harris","year":"2019","unstructured":"Harris RE, Armstrong L, Curtis L, Garrick V, Gervais L, Tayler R, Hansen R, Russell RK (2019) Severe hypophosphataemia following ferric carboxymaltose infusion in paediatric patients with inflammatory bowel disease. Frontline Gastroenterol 11:324\u2013326. https:\/\/doi.org\/10.1136\/flgastro-2019-101242","journal-title":"Frontline Gastroenterol"},{"issue":"Suppl 1","key":"4582_CR51","doi-asserted-by":"publisher","first-page":"S583","DOI":"10.1093\/ecco-jcc\/jjx180.1049","volume":"12","author":"K Crook","year":"2018","unstructured":"Crook K, Tyrrell T, Hyer W (2018) N035 The use of intravenous (IV) ferric carboxymaltose in a paediatric IBD population. J Crohns Colitis 12(Suppl 1):S583\u2013S584. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjx180.1049","journal-title":"J Crohns Colitis"},{"issue":"S1","key":"4582_CR52","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/cpdd.610","volume":"7","author":"J Jones","year":"2018","unstructured":"Jones J, Butcher A, Rodgers T, Farrell C, Blackman N (2018) Poster number: 007 Pharmacokinetic\/pharmacodynamic modeling of intravenous ferric carboxymaltose in pediatric subjects with iron deficiency anemia. Clin Pharmacol Drug Dev 7(S1):5\u20136. https:\/\/doi.org\/10.1002\/cpdd.610","journal-title":"Clin Pharmacol Drug Dev"},{"key":"4582_CR53","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.jpeds.2017.01.041","volume":"184","author":"E Mantadakis","year":"2017","unstructured":"Mantadakis E, Roganovic J (2017) Safety and efficacy of ferric carboxymaltose in children and adolescents with iron deficiency anemia. J Pediatr 184:241. https:\/\/doi.org\/10.1016\/j.jpeds.2017.01.041","journal-title":"J Pediatr"},{"key":"4582_CR54","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.124486","volume":"3","author":"M Wolf","year":"2018","unstructured":"Wolf M, Chertow GM, Macdougall IC, Kaper R, Krop J, Strauss W (2018) Randomized trial of intravenous iron-induced hypophosphatemia. JCI Insight 3:e124486. https:\/\/doi.org\/10.1172\/jci.insight.124486","journal-title":"JCI Insight"},{"key":"4582_CR55","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1001\/jama.2019.22450","volume":"323","author":"M Wolf","year":"2020","unstructured":"Wolf M, Rubin J, Achebe M, Econs MJ, Peacock M, Imel EA, Thomsen LL, Carpenter TO, Weber T, Brandenburg V, Zoller H (2020) Effects of iron isomaltoside vs ferric carboxymaltose on hypophosphatemia in iron-deficiency anemia: two randomized clinical trials. JAMA 323:432\u2013443. https:\/\/doi.org\/10.1001\/jama.2019.22450","journal-title":"JAMA"},{"key":"4582_CR56","doi-asserted-by":"publisher","first-page":"245","DOI":"10.2147\/TCRM.S243462","volume":"16","author":"JA Glaspy","year":"2020","unstructured":"Glaspy JA, Lim-Watson MZ, Libre MA, Karkare SS, Hadker N, Bajic-Lucas A, Strauss WE, Dahl NV (2020) Hypophosphatemia associated with intravenous iron therapies for iron deficiency anemia: a systematic literature review. Ther Clin Risk Manag 16:245\u2013259. https:\/\/doi.org\/10.2147\/TCRM.S243462","journal-title":"Ther Clin Risk Manag"},{"key":"4582_CR57","doi-asserted-by":"publisher","unstructured":"Hussain I, Bhoyroo J, Butcher A, Koch TA, He A, Bregman DB (2013) Direct comparison of the safety and efficacy of ferric carboxymaltose versus iron dextran in patients with iron deficiency anemia. Anemia 2013:169107.\u00a0https:\/\/doi.org\/10.1155\/2013\/169107","DOI":"10.1155\/2013\/169107"},{"key":"4582_CR58","doi-asserted-by":"publisher","unstructured":"Wolf M, Koch TA, Bregman DB (2013) Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women. J Bone Miner Res 28:1793\u20131803. https:\/\/doi.org\/10.1002\/jbmr.1923","DOI":"10.1002\/jbmr.1923"},{"key":"4582_CR59","doi-asserted-by":"publisher","unstructured":"Huang LL, Lee D, Troster SM, Kent AB, Roberts MA, Macdougall IC, McMahon LP (2018) A controlled study of the effects of ferric carboxymaltose on bone and haematinic biomarkers in chronic kidney disease and pregnancy. Nephrol Dial Transplant 33:1628\u20131635. https:\/\/doi.org\/10.1093\/ndt\/gfx310","DOI":"10.1093\/ndt\/gfx310"},{"key":"4582_CR60","unstructured":"Venofer (iron sucrose) Summary of product characteristics (2021) Available at: https:\/\/www.medicines.org.uk\/emc\/product\/5911\/smpc#gref. (Accessed May 2022)"},{"issue":"Suppl","key":"4582_CR61","doi-asserted-by":"publisher","first-page":"S407","DOI":"10.1093\/ecco-jcc\/jjab076.522","volume":"15","author":"N Bevers","year":"2021","unstructured":"Bevers N, van de Vijver E, Aliu A, Rezazadeh Ardabili A, Rosias P, Busari J, Stapelbroek J, Bertrams I, van der Feen C, Oudshoorn A, Teklenburg S, Escher J, Vande Velde S, Winkens B, Raijmakers M, Vreugdenhil A, Pierik M, van Rheenen P (2021) P398 effect of intravenous versus oral iron therapy on physical fitness and haemoglobin in paediatric IBD patients with anaemia. J Crohns Colitis 15(Suppl):S407\u2013S408. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjab076.522","journal-title":"J Crohns Colitis"}],"container-title":["European Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-022-04582-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00431-022-04582-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-022-04582-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,8]],"date-time":"2022-10-08T02:03:09Z","timestamp":1665194589000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00431-022-04582-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,2]]},"references-count":61,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,11]]}},"alternative-id":["4582"],"URL":"https:\/\/doi.org\/10.1007\/s00431-022-04582-w","relation":{},"ISSN":["1432-1076"],"issn-type":[{"value":"1432-1076","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,2]]},"assertion":[{"value":"8 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ayseg\u00fcl Aksan has received consultation fees and research funding from Vifor Pharma and Immundiagnostik AG. Sangeetha Anand is an employee of Vifor Pharma. J\u00fcrgen Stein has received consulting fees or honoraria from Abbvie, Bristol Myers Squibb, Dr. Sch\u00e4r, Falk, Ferring, Fresenius Kabi, Gallapagos, Immundiagnostik, Janssen, Medice, MSD, Pfizer, Pharmacosmos, Shire, Shield, Takeda, Thermo Fisher and Vifor Pharma. Fred Zepp is a member of the Data Safety Monitoring Boards (DSMB) for the development of COVID-19 vaccines (CureVac and Icosavax) and RS vaccines (Icosavax). He also serves as a DSMB observer for vaccine trials sponsored by CEPI.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}